BMC Public Health · Nov 17, 2026

The double burden paradox: sarcopenic obesity prevalence and predictors in the Indian adult population: a systematic review and meta-analysis

By Shrivastav VN, Sakurkar M, Nagrecha VT et al.

Background Sarcopenic obesity (SO) — the coexistence of reduced skeletal muscle mass or strength with excess adiposity — is gaining recognition as a clinically significant phenotype, particularly in transitional populations. India faces a uniquely compounded risk owing to its accelerating obesity epidemic, widespread protein insufficiency, and a rapidly ageing population projected to reach 319 million elderly by 2050. Despite this burden, no nationwide synthesis of SO prevalence or its determinants existed for Indian adults. Methods We conducted a systematic review and meta-analysis (PROSPERO: CRD420251086122) following PRISMA 2020 guidelines. PubMed, Embase, Scopus, and Web of Science were searched from inception without date restrictions, supplemented by Google Scholar and citation tracking for grey literature. Studies reporting SO prevalence in Indian adults (≥ 18 years, defined by study location/residence in India) using validated diagnostic frameworks (AWGS 2014/2019, EWGSOP2, or Baumgartner criteria) were eligible. Pooled prevalence was estimated using a random-effects model with Freeman–Tukey double-arcsine transformation. The single case-control study identified was excluded from the primary prevalence pool, given the structural unsuitability of case-control sampling for prevalence estimation, and was instead analysed in a separate inclusive sensitivity analysis. Heterogeneity, publication bias, subgroup analyses, meta-regression, and influence diagnostics were systematically performed. Results Sixteen studies comprising 174,907 Indian adults met eligibility criteria. Fifteen cross-sectional studies (174,807 adults) formed the primary prevalence pool; the single case-control study (Paila et al.) was analysed separately. The primary pooled SO prevalence was 15.8% (95% CI: 12.9–18.9%; I² = 99.3%). When the case-control study was added in an inclusive sensitivity analysis (16 studies, 174,907 adults), the pooled estimate rose to 17.1% (95% CI: 14.2–20.3%), with a prediction interval of 6.9–30.7% and extreme heterogeneity (I² = 99.5%). All subgroup, meta-regression, and publication-bias analyses were conducted on the full 16-study dataset for exploratory purposes and are reported alongside these primary figures. Community-based studies yielded 13.5%, while hospital-based studies reported 25.5%. AWGS 2019-based studies produced a pooled estimate of 17.4%. Diabetes mellitus (aOR 2.49; 95% CI: 1.45–4.28) and cardiovascular disease (aOR 2.19; 95% CI: 1.17–4.09) were the strongest comorbid predictors. A significant positive temporal trend was observed, with SO prevalence rising over the decade 2016–2026; given the very low overall GRADE certainty, this trend should be regarded as hypothesis-generating. Conclusion Among the 15 cross-sectional studies forming the primary analysis, pooled SO prevalence was 15.8% (95% CI: 12.9–18.9%); this rose to 17.1% (95% CI: 14.2–20.3%) in an inclusive sensitivity analysis adding the single case-control study (Paila et al.), which we consider structurally unsuited to prevalence estimation. Among studies applying AWGS 2019 — the framework recommended for South Asian populations — the pooled estimate was 17.4% (95% CI: 14.3–20.7%). The two largest national community surveys reported 8.7% and 10.6%, anchoring real-world community burden at 8–11%. Given extreme between-study heterogeneity (I²≥99%), diverse diagnostic criteria, a mix of community and hospital populations, and an overall GRADE certainty rating of very low, these figures should be read as characterising the distribution of SO estimates in the Indian literature rather than a single precise population-level prevalence, and findings are specific to India and should not be extrapolated to South Asia more broadly. With this caveat, the findings are compatible with integrating sarcopenia screening into national NCD programmes and working toward standardised diagnostic protocols around AWGS 2019 with Asian BMI thresholds, pending confirmation in higher-certainty prospective studies.

doi.org/10.1186/s12889-026-30351-7Open accessPopulations

AgingResearch.News